Literature DB >> 18369681

Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients.

Giorgio Ricci1, Gianluca Bersani, Angelo Rossi, Flavia Pigò, Giovanni De Fabritiis, Vittorio Alvisi.   

Abstract

BACKGROUND: Obesity is often associated with fatty liver (FL). In most cases, bright liver at ultrasound (US) and increased alanine aminotransferase (ALT) and gamma-glutamyltranspeptidase (GGT) levels are considered the hallmarks of nonalcoholic fatty liver disease (NAFLD). Insulin resistance (IR) is the main link between obesity and NAFLD. The use of the Bioenterics intragastric balloon (BIB) is a safe procedure either for inducing a sustained weight loss with diet support or for preparing those patients who are candidates for bariatric surgery. The aim of the study was to investigate whether the weight loss induced by intragastric balloon might improve IR and liver enzymes. The presence or absence of FL at US and the influence of a body mass index (BMI) decrease > or = 10% after BIB (DeltaBMI > or = 10%) were also considered.
METHODS: One hundred and three consecutive obese (BMI > 30 kg/m(2)) patients (38 males/65 females; mean age 41.3, range 20-63 years) underwent BIB insertion under endoscopic control. The BIB was removed 6 months later. US, clinical, and routine laboratory investigations were performed before and after BIB. IR was calculated by the homeostasis model assessment (HOMA-IR > 2.5). Exclusion criteria were hepatitis B virus positive, hepatitis C virus positive, alcohol consumption >30 g/day, history of hepato-steatogenic drugs, and type 1 diabetes.
RESULTS: Ninety-three patients were eligible for the study. The BMI significantly decreased in all investigated patients, and it was > or = 10% in 59% of the patients. FL was seen at US in 70%, impaired fasting blood glucose was present in 13%, ALT exceeded the normal limit in 30.1%, GGT exceeded the normal limit in 15%, and HOMA-IR was >2.5 in 85%. Median HOMA-IR decreased significantly in FL (4.71 vs 3.10; p < 0.05) and non-FL (3.72 vs 2.81; p < 0.01) groups. Median ALT decreased significantly in the FL group (31.5 vs 24; p < 0.001) and GGT significantly decreased in the FL group (31 vs 23.5; p < 0.05). In the FL group with DeltaBMI > or = 10%, the median values of HOMA-IR (4.95 vs 2.69; p < 0.05), ALT (30 vs 23; p < 0.01), and GGT (28 vs 20; p < 0.001) significantly decreased after BIB. In the non-FL group, HOMA-IR values significantly decreased (4.07 vs 2.36; p < 0.01) in patients with a DeltaBMI > or = 10%; ALT and GGT did not significantly decrease.
CONCLUSIONS: Weight loss induced by intragrastric balloon reduces IR. The ALT and GGT decrease suggests an improvement in hepatic damage. The benefit depends on the decrease of BMI higher than 10%.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18369681     DOI: 10.1007/s11695-008-9487-x

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  18 in total

1.  Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome.

Authors:  G Marchesini; S Avagnina; E G Barantani; A M Ciccarone; F Corica; E Dall'Aglio; R Dalle Grave; P S Morpurgo; F Tomasi; E Vitacolonna
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

2.  BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients.

Authors:  A Genco; M Cipriano; V Bacci; M Cuzzolaro; A Materia; L Raparelli; C Docimo; M Lorenzo; N Basso
Journal:  Int J Obes (Lond)       Date:  2006-01       Impact factor: 5.095

Review 3.  Insulin resistance: a metabolic pathway to chronic liver disease.

Authors:  Elisabetta Bugianesi; Arthur J McCullough; Giulio Marchesini
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

Review 4.  Review: The role of insulin resistance in nonalcoholic fatty liver disease.

Authors:  Kristina M Utzschneider; Steven E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

5.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

6.  The effect of loss of excess weight on the metabolic risk factors after bariatric surgery in morbidly and super-obese patients.

Authors:  Anna Maria Wolf; Ulrike Beisiegel
Journal:  Obes Surg       Date:  2007-07       Impact factor: 4.129

7.  Intragastric balloon insertion increases the frequency of erosive esophagitis in obese patients.

Authors:  Angelo Rossi; Gianluca Bersani; Giorgio Ricci; Chiara Petrini; Giovanni DeFabritiis; Vittorio Alvisi
Journal:  Obes Surg       Date:  2007-10       Impact factor: 4.129

8.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Relationship of liver enzymes to insulin sensitivity and intra-abdominal fat.

Authors:  Tara M Wallace; Kristina M Utzschneider; Jenny Tong; Darcy B Carr; Sakeneh Zraika; Daniel D Bankson; Robert H Knopp; Steven E Kahn
Journal:  Diabetes Care       Date:  2007-07-31       Impact factor: 19.112

10.  Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life.

Authors:  I J Hickman; J R Jonsson; J B Prins; S Ash; D M Purdie; A D Clouston; E E Powell
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

View more
  13 in total

Review 1.  Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis.

Authors:  Saurabh Chandan; Babu P Mohan; Shahab R Khan; Antonio Facciorusso; Daryl Ramai; Lena L Kassab; Neil Bhogal; Ravishankar Asokkumar; Gortrand Lopez-Nava; Stephanie McDonough; Douglas G Adler
Journal:  Obes Surg       Date:  2021-01-06       Impact factor: 4.129

Review 2.  Filling the Void: A Review of Intragastric Balloons for Obesity.

Authors:  Patrick Laing; Tuan Pham; Linda Jo Taylor; John Fang
Journal:  Dig Dis Sci       Date:  2017-04-18       Impact factor: 3.199

3.  Bariatric Surgery and Liver Function Tests in Nonalcoholic Fatty Liver Disease.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Obes Surg       Date:  2017-04       Impact factor: 4.129

Review 4.  Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.

Authors:  Kareem Hassan; Varun Bhalla; Mohammed Ezz El Regal; H Hesham A-Kader
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

5.  Intragastric balloon treatment for obesity: results of a large single center prospective study.

Authors:  Davor Stimac; Sanja Klobučar Majanović; Tamara Turk; Borivoj Kezele; Vanja Licul; Zeljka Crnčević Orlić
Journal:  Obes Surg       Date:  2011-05       Impact factor: 4.129

Review 6.  The Impact of Intragastric Balloons on Obesity-Related Co-Morbidities: A Systematic Review and Meta-Analysis.

Authors:  Violeta B Popov; Amy Ou; Allison R Schulman; Christopher C Thompson
Journal:  Am J Gastroenterol       Date:  2017-01-24       Impact factor: 10.864

Review 7.  Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis.

Authors:  Violeta B Popov; Christopher C Thompson; Nitin Kumar; Maria M Ciarleglio; Yanhong Deng; Loren Laine
Journal:  Dig Dis Sci       Date:  2016-05-20       Impact factor: 3.199

Review 8.  Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

Authors:  Kathleen E Corey; Mary E Rinella
Journal:  Dig Dis Sci       Date:  2016-03-04       Impact factor: 3.199

9.  Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis.

Authors:  Nicola Crea; Giacomo Pata; Domenico Della Casa; Luigi Minelli; Giovanni Maifredi; Ernesto Di Betta; Francesco Mittempergher
Journal:  Obes Surg       Date:  2009-06-09       Impact factor: 4.129

10.  Impact on obesity-related illnesses and quality of life following intragastric balloon.

Authors:  Wilfred Lik-Man Mui; Enders Kwok-Wai Ng; Bonnie Yuk-San Tsung; Chuen Hing Lam; Man Yee Yung
Journal:  Obes Surg       Date:  2008-11-18       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.